Apellis Pharmaceuticals, Inc. (APLS) stock rallied over 0.07% intraday to trade at $45.22 a share on NASDAQ. The stock opened with a gain of 2.82% at $44.15 and touched an intraday high of $45.97, rising 0.07% against the last close of $45.19. The stock went to a low of $43.59 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue66.56 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock price is $45.22 as of the last check on Thursday, June 30. During the trading session, APLS stock reached the peak price of $45.97 while $43.59 was the lowest point it dropped to.
The NASDAQ listed APLS is part of Biotechnology industry that operates in the broader Health Care sector. Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
Mr. Alec Machiels J.D., MBA
Co-Founder & Independent Director
Mr. Timothy E. Sullivan
Chief Financial Officer
Dr. Cedric Francois M.D., Ph.D.
Co-Founder, Pres, CEO & Director
Dr. Pascal Deschatelets Ph.D.
Co-Founder & Chief Scientific Officer
APLS stock traded closed the last session at $45.22, which is $0.03 or 0.07% lower than its previous close of $45.19. APLS's current trading price is 64.44% lower than its 52-week high of $73.00 where as its distance from 52-week low of 27.50% is -38.05%.
Number of APLS employees currently stands at -. APLS operates from 100 Fifth Avenue, Waltham, MA 02451, United States.
Official Webiste of $APLS is: https://www.apellis.com
APLS stock volume for the day was 709,601 shares while in the previous session number of APLS shares traded was 683,229 . The average number of APLS shares traded daily for last 3 months was 1.03 Million.
The percentage change in APLS stock occurred in the recent session was 0.07% while the dollar amount for the price change in APLS stock was $0.03.
In the recent session, the day high for APLS stock was $45.97 while the low for APLS stock touched on the day was $43.59.
The market value of APLS currently stands at 4.89 Billion with its latest stock price at $45.22 and 98.07 Million of its shares outstanding.